Lipocine’s LPCN 1154 did not meet endpoint in postpartum depression trial

Lipocine (LPCN) announced topline results from its Phase 3 placebo-controlled trial evaluating LPCN 1154 – oral brexanolone – for the treatment of postpartum depression, or PPD. LPCN 1154 did not show a statistically significant reduction from baseline in HAM-D total score compared to placebo at hour 60 in the full analysis set and the primary was not met. The results showed LPCN 1154 to be well tolerated and demonstrated a favorable safety profile to support outpatient administration without the need for healthcare provider monitoring. No treatment-related severe or serious adverse events were reported; no cases of excessive sedation or loss of consciousness were observed; and no treatment-related discontinuations were reported. The company identified signals that could indicate a potential development path for LPCN 1154. The company has applied for breakthrough therapy and fast track designations for LPCN 1154 in patients with PPD. While the company is waiting for feedback from the FDA on such designations, the company plans to preserve capital and engage with stakeholders, including investors, regulators, and advisors, to evaluate all options available to the company going forward. Such options may include, but are not limited to, continued development of LPCN 1154, including the potential submission of a validation study protocol, development of other product candidates, strategic transactions, partnerships, and other opportunities.